source
- Acadia’s Alzheimer’s psychosis drug misses Phase 2 goals, but moves to revised Phase 3Acadia Pharmaceuticals announced that its experimental treatment for psychosis linked to Alzheimer’s disease failed to meet the primary endpoints in a Phase 2 trial. The company said the data stil…
- Kyverna reports durable responses in early cell therapy trial for autoimmune diseaseKyverna Therapeutics announced new data from its cell therapy candidate targeting an autoimmune condition, marking progress toward a potential first‑in‑class product. The results showed that a not…